Laidlaw analyst Francois Brisebois said the FDA agreeing to Avadel Pharmaceuticals' amendments to the statistical analysis plan and protocol enables the company to lower their sample size to demonstrate statistical significance for excessive daytime sleepiness as well as cataplexy in narcolepsy patients. The company now expects to complete enrollment by YE19 and have topline data in 2Q20, which Brisebois said is about a year ahead of schedule. The analyst, who views the FDA's acceptance of the amendments as "a clear testament of execution and focus on FT-218," reiterated his Buy rating on Avadel shares and raised his price target on the stock to $6 from $3.